跳到正文
原文
Nature Medicine· Elias S. Sotirchos·· 12 小时前AI 评分40

关于奥比珠单抗β在AQP4-IgG阳性NMOSD临床试验中使用安慰剂的伦理争议

Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder

AI 导读

Wu等人报道的一项针对AQP4-IgG阳性神经肌病视神经炎谱系障碍(NMOSD)患者的奥比珠单抗β(MIL62)三期随机对照试验显示,MIL62治疗显著降低了复发风险。作者认为使用安慰剂不道德且违反了赫尔辛基宣言。该试验在中国32个中心进行,于2022年8月启动。

正文
  • Matters Arising
  • Published: 20 November 2026

Nature Medicine (2026) Cite this article

arising from L. Wu et al. Nature Medicine https://doi.org/10.1038/s41591-026-04583-4 (2026)

Aquaporin-4 (AQP4) immunoglobulin G (IgG) seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disorder of the central nervous system, characterized by severe and often permanently disabling attacks of optic neuritis, myelitis and cerebral or brainstem syndromes1. Wu et al.2 reported the results of a phase 3, randomized, placebo-controlled trial of obinutuzumab β (MIL62) in people with AQP4-IgG+ NMOSD, conducted at 32 centers across China, with study start in August 2022. The trial demonstrated markedly decreased risk of relapse in MIL62-treated participants versus placebo. We argue that the use of a placebo in this trial was unjustified and unethical, and violated the principles of the Declaration of Helsinki.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

32.70 € / 30 days cancel any time

Learn more

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177–189 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Wu, L. et al. Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. Nat. Med. 32, 3672–3681 https://doi.org/10.1038/s41591-026-04583-4 (2026).

  3. Mealy, M. A. et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult. Scler. Relat. Disord. 28, 64–68 (2019).

    Article  PubMed  Google Scholar 

  4. Cree, B. A. C. et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet Lond. Engl. 394, 1352–1363 (2019).

    Article  CAS  Google Scholar 

  5. Tahara, M. et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 19, 298–306 (2020).

    Article  CAS  PubMed  Google Scholar 

  6. Pittock, S. J. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 614–625 (2019).

    Article  CAS  PubMed  Google Scholar 

  7. Yamamura, T. et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 2114–2124 (2019).

    Article  CAS  PubMed  Google Scholar 

  8. Traboulsee, A. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 19, 402–412 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pittock, S. J., Zekeridou, A. & Weinshenker, B. G. Hope for patients with neuromyelitis optica spectrum disorders—from mechanisms to trials. Nat. Rev. Neurol. 17, 759–773 (2021).

    Article  CAS  PubMed  Google Scholar 

  10. Pittock, S. J. et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann. Neurol. 93, 1053–1068 (2023).

    Article  CAS  PubMed  Google Scholar 

  11. Barreras, P. et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology 99, e2504–e2516 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wu, L. et al. Safety and efficacy of obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD20 monoclonal antibody, in patients with neuromyelitis optica spectrum disorder: a multicenter, single-arm, phase Ib clinical trial. Neurol. Ther. 15, 1845–1862 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  13. WMA Declaration of Helsinki – ethical principles for medical research involving human participants. https://www.wma.net/policies-post/wma-declaration-of-helsinki/ (WMA, 2024).

  14. Weinshenker, B. G. et al. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology 84, 1805–1815 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rhodes, R. A placebo controlled trial for an NMO relapse prevention treatment: ethical considerations. Mult. Scler. Relat. Disord. 4, 580–584 (2015).

    Article  PubMed  Google Scholar 

  16. Levy, M. The ethics of placebo controlled clinical trials in NMO - a balance of risks. Mult. Scler. Relat. Disord. 4, 512–514 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cree, B. A. C. Placebo controlled trials in neuromyelitis optica are needed and ethical. Mult. Scler. Relat. Disord. 4, 536–545 (2015).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Elias S. Sotirchos

  2. Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

    Deanna Saylor

Authors

  1. Elias S. Sotirchos
  2. Deanna Saylor

Contributions

E.S.S. and D.S. drafted, critically reviewed, edited and approved the final version of the paper.

Corresponding author

Correspondence to Elias S. Sotirchos.

Ethics declarations

Competing interests

E.S.S. has served on advisory boards for Alexion, Roche/Genentech, UCB and Amgen; has provided non-promotional speaking for Alexion and Roche/Genentech; is site Principal Investigator for contract research for Alexion, Roche/Genentech, UCB, Ad Scientiam and CorEvitas; and has received research funding from the National Multiple Sclerosis Society, National Institutes of Health, Patient-Centered Outcomes Research Institute, Department of Defense and Astoria Biologica. D.S. has received research funding from the National Multiple Sclerosis Society, the American Academy of Neurology, the American Heart Association and the National Institutes of Health, and has received travel support for meetings from the National Multiple Sclerosis Society and the European Committee on Treatment and Research in Multiple Sclerosis.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sotirchos, E.S., Saylor, D. Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Nat Med (2026). https://doi.org/10.1038/s41591-026-04781-0

Download citation

  • Received: 18 September 2026

  • Accepted: 26 October 2026

  • Published: 20 November 2026

  • Version of record: 20 November 2026

  • DOI: https://doi.org/10.1038/s41591-026-04781-0

来源:Nature Medicine · nature.com